Merck reports data from Phase III gastric cancer treatment trial

Merck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial evaluating Keytruda (pembrolizumab) plus trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.